此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

Natalizumab High Titer Immunogenicity and Safety

2014年5月1日 更新者：Biogen

A Multicenter, Open-Label Immunogenicity and Safety Study of Natalizumab High Titer Material (BG00002-E) in Subjects With Relapsing Forms of Multiple Sclerosis

The primary objective of the study was to evaluate the immunogenicity of natalizumab (Tysabri®) produced by a modified manufacturing process (natalizumab high titer; BG00002-E) administered intravenously (IV) to participants with relapsing forms of multiple sclerosis (MS). The secondary objective of this study was to evaluate the safety of natalizumab high titer.

研究概览

地位

完全的

条件

干预/治疗

研究类型

介入性

注册 (实际的)

113

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

  • 美国
    • District of Columbia
      • Washington、District of Columbia、美国、20007
        • Research Site
    • Florida
      • Maitland、Florida、美国、32751
        • Research Site
      • Miami、Florida、美国、33136
        • Research Site
    • Georgia
      • Atlanta、Georgia、美国、30327
        • Research Site
    • Michigan
      • Farmington Hills、Michigan、美国、48334
        • Research Site
    • New York
      • Buffalo、New York、美国、14203
        • Research Site
      • New York、New York、美国、10003
        • Research Site
    • North Carolina
      • Charlotte、North Carolina、美国、28207
        • Research Site
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104
        • Research Site
      • Pittsburgh、Pennsylvania、美国、15212
        • Research Site
    • Texas
      • Dallas、Texas、美国、75214
        • Research Site
      • Round Rock、Texas、美国、78681
        • Research Site
    • Wisconsin
      • Milwaukee、Wisconsin、美国、53215
        • Research Site

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 55年 (成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Diagnosis of a relapsing form of MS
  • Must fall within the therapeutic indications stated in the locally approved label for natalizumab
  • Other protocol-defined inclusion criteria may apply

Exclusion Criteria:

  • Prior treatment with natalizumab
  • Considered by investigator to be immunocompromised
  • Other protocol-defined exclusion criteria may apply

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 分配：不适用
  • 介入模型：单组作业
  • 屏蔽：无（打开标签）

武器和干预

参与者组/臂
干预/治疗
实验性的：Natalizumab High Titer
natalizumab high titer 300 mg administered as intravenous (IV) infusion over 60 minutes once every 4 weeks for up to 9 doses
生物：BG00002-E (natalizumab high titer)
其他名称：
  • 蒂萨布里

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Number of Participants With Anti-Natalizumab Antibody Negative, Transient Positive, and Persistent Positive Status
大体时间：Assessed every 12 weeks from Week 0 (Baseline) to Week 36
Negative: no detectable antibody at all post-baseline visits. Persistent positive: antibody positive at 2 or more post-baseline visits at least 42 days apart, or positive at the last post-baseline visit. Transient positive: antibody positive at only 1 post-baseline visit prior to the last visit.
Assessed every 12 weeks from Week 0 (Baseline) to Week 36

次要结果测量

结果测量
措施说明
大体时间
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs
大体时间：AEs: collected from Baseline (Week 0) until Week 36 or premature withdrawal. SAEs: collected from informed consent until Week 36 or premature withdrawal.
AE: any sign, symptom, or diagnosis/disease that was unfavorable or unintended, new, or if pre-existing, worsened in a participant administered a study treatment and that did not necessarily have a causal relationship with this treatment. SAE: an event that resulted in death; an event that, in the view of the investigator, placed the participant at immediate risk of death (life-threatening event); an outcome that resulted in a congenital anomaly/birth defect diagnosed in a child of a participant in this study; an event that required or prolonged inpatient hospitalization; an event that resulted in persistent or significant disability/incapacity; any other medically important event that, in the opinion of the investigator, may have jeopardized the participant or may have required intervention to prevent one of the other outcomes listed above. Events were classified as 'related' or 'not related' to study drug, and categorized as 'mild' moderate' or 'severe' per protocol.
AEs: collected from Baseline (Week 0) until Week 36 or premature withdrawal. SAEs: collected from informed consent until Week 36 or premature withdrawal.
Mean Change From Baseline in Expanded Disability Status Scale (EDSS) Scores at Week 36
大体时间：Baseline, Week 36
EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. The change in EDSS at Month 36 was calculated as EDSS at Month 36 minus EDSS at baseline.
Baseline, Week 36
Annualized Relapse Rate
大体时间：Through Week 36
Annualized relapse rate was calculated as the total number of relapses that occurred during the study divided by the total number of years the participant was followed in the study. The annualized relapse rate was based only on those relapses that were determined to meet the definition of relapse per the investigator's clinical judgment. New or recurrent symptoms that occurred less than 30 days following the onset of a protocol-defined relapse were considered part of the same relapse.
Through Week 36

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Biogen

合作者

Elan Pharmaceuticals

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2006年10月1日

初级完成 (实际的)

2007年10月1日

研究完成 (实际的)

2007年12月1日

研究注册日期

首次提交

2007年8月14日

首先提交符合 QC 标准的

2007年8月15日

首次发布 (估计)

2007年8月16日

研究记录更新

最后更新发布 (估计)

2014年5月15日

上次提交的符合 QC 标准的更新

2014年5月1日

最后验证

2014年5月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • 101MS201

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅